Recurrence is Not Associated with Margin Status in Phyllodes Tumor.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
28
09
2022
accepted:
09
12
2022
pubmed:
4
1
2023
medline:
23
3
2023
entrez:
3
1
2023
Statut:
ppublish
Résumé
Phyllodes tumor (PT) is a rare fibroepithelial neoplasm of the breast. The proper extent of resection is still under debate. This study aimed to investigate the optimal surgical margin to prevent recurrence after surgery for PT and to evaluate risk factors for local recurrence (LR). Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for PT at Seoul National University Bundang Hospital between July 2003 and February 2022 were reviewed. Of the 439 patients included, 285 were benign, 129 were borderline, and 25 were malignant. There was no statistically significant difference in 5-year disease-free survival (DFS) between margin-negative and margin-involved patients (87.3% vs. 85.1%, p = 0.081). When patients were classified into groups, according to margin status, as conventional (≥ 1 cm from tumor), close (< 1 cm from tumor), or involved, 5-year DFS rates were also similar (100% vs. 86.9% vs. 85.1%, p = 0.170). In subgroup analysis for different histologic grades, 5-year DFS was not affected by margin involvement. In univariate analysis, large tumor size (> 5 cm; hazard ratio [HR] 2.857, p = 0.028) and infiltrative tumor border (HR 3.096, p = 0.012) were independent risk factors for LR. Further multivariate analysis found both factors to be prognostic. Recurrence was not significantly influenced by margin status in all histological grades. In benign and borderline tumors, local excision without wide surgical margins could be sufficient, and watchful waiting could be an option for patients with positive margins after initial surgery.
Sections du résumé
BACKGROUND
BACKGROUND
Phyllodes tumor (PT) is a rare fibroepithelial neoplasm of the breast. The proper extent of resection is still under debate. This study aimed to investigate the optimal surgical margin to prevent recurrence after surgery for PT and to evaluate risk factors for local recurrence (LR).
METHODS
METHODS
Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for PT at Seoul National University Bundang Hospital between July 2003 and February 2022 were reviewed.
RESULTS
RESULTS
Of the 439 patients included, 285 were benign, 129 were borderline, and 25 were malignant. There was no statistically significant difference in 5-year disease-free survival (DFS) between margin-negative and margin-involved patients (87.3% vs. 85.1%, p = 0.081). When patients were classified into groups, according to margin status, as conventional (≥ 1 cm from tumor), close (< 1 cm from tumor), or involved, 5-year DFS rates were also similar (100% vs. 86.9% vs. 85.1%, p = 0.170). In subgroup analysis for different histologic grades, 5-year DFS was not affected by margin involvement. In univariate analysis, large tumor size (> 5 cm; hazard ratio [HR] 2.857, p = 0.028) and infiltrative tumor border (HR 3.096, p = 0.012) were independent risk factors for LR. Further multivariate analysis found both factors to be prognostic.
CONCLUSIONS
CONCLUSIONS
Recurrence was not significantly influenced by margin status in all histological grades. In benign and borderline tumors, local excision without wide surgical margins could be sufficient, and watchful waiting could be an option for patients with positive margins after initial surgery.
Identifiants
pubmed: 36596955
doi: 10.1245/s10434-022-12997-w
pii: 10.1245/s10434-022-12997-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2154-2161Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Rosenberger LH, Thomas SM, Nimbkar SN, et al. Contemporary multi-institutional cohort of 550 cases of phyllodes tumors (2007–2017) demonstrates a need for more individualized margin guidelines. J Clin Oncol. 2020;39(3):178–89.
doi: 10.1200/JCO.20.02647
pubmed: 33301374
pmcid: 8462612
Lakhani S, Ellis I, Schnitt S, et al. World Health Organization (WHO) classification of tumors of the breast. 4th edn. Lyon: International Agency for Research on Cancer; 2012. p. 142–7.
Lu Y, Chen Y, Zhu L, et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Ann Surg Oncol. 2019;26(5):1263–75. https://doi.org/10.1245/s10434-018-07134-5 .
doi: 10.1245/s10434-018-07134-5
pubmed: 30617873
National Comprehensive Cancer Network. Breast cancer. NCCN clinical practice guidelines in oncology. Version 4, 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf .
Shaaban M, Barthelmes L. Benign phyllodes tumours of the breast: (over) treatment of margins—a literature review. Eur J Surg Oncol. 2017;43(7):1186–90.
doi: 10.1016/j.ejso.2016.10.019
pubmed: 27939569
Tremblay-LeMay R, Hogue JC, Provencher L, et al. How wide should margins be for phyllodes tumors of the breast? Breast J. 2017;23:315–22.
doi: 10.1111/tbj.12727
pubmed: 27901301
Yom CK, Han W, Kim SW, Park SY, Park IA, Noh DY. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol. 2015;22:2912–8. https://doi.org/10.1245/s10434-015-4395-5 .
doi: 10.1245/s10434-015-4395-5
pubmed: 25652050
Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19:2612–7. https://doi.org/10.1245/s10434-012-2307-5 .
doi: 10.1245/s10434-012-2307-5
pubmed: 22476816
Moo TA, Alabdulkareem H, Tam A, et al. Association between recurrence and re-excision for close and positive margins versus observation in patients with benign phyllodes tumors. Ann Surg Oncol. 2017;24(10):3088–92. https://doi.org/10.1245/s10434-017-5955-7 .
doi: 10.1245/s10434-017-5955-7
pubmed: 28766221
Ji Y, Zhong Y, Zheng Y, et al. Surgical management and prognosis of phyllodes tumors of the breast. Gland Surg. 2022;11(6):981–91.
doi: 10.21037/gs-21-877
pubmed: 35800748
pmcid: 9253188
Choi JE, Kang SH, Tan PH, Bae YK. Recurrence prediction for breast phyllodes tumours: validation of the Singapore nomogram in Korean women. J Clin Pathol. 2022;75(3):159–63.
doi: 10.1136/jclinpath-2020-207093
pubmed: 33376198
Chao X, Jin X, Tan C, et al. Re-excision or “wait and watch”-a prediction model in breast phyllodes tumors after surgery. Ann Transl Med. 2020;8(6):371.
doi: 10.21037/atm.2020.02.26
pubmed: 32355815
pmcid: 7186749
Kim S, Kim JY, Kim DH, Jung WH, Koo JS. Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat. 2013;141(3):353–63.
doi: 10.1007/s10549-013-2684-x
pubmed: 24062207
Lawton TJ, Acs G, Argani P, et al. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol. 2014;22(8):695–8.
doi: 10.1177/1066896914548763
pubmed: 25161205
pmcid: 4352312
Tsang AK, Chan SK, Lam CC, et al. Phyllodes tumours of the breast—differentiating features in core needle biopsy. Histopathology. 2011;59(4):600–8.
doi: 10.1111/j.1365-2559.2011.03939.x
pubmed: 21916949
El Hag IA, Aodah A, Kollur SM, Attallah A, Mohamed AA, Al-Hussaini H. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. Cancer Cytopathol. 2010;118(1):33–40.
doi: 10.1002/cncy.20057
pubmed: 20094997
Toussaint A, Piaget-Rossel R, Stormacq C, Mathevet P, Lepigeon K, Taffé P. Width of margins in phyllodes tumors of the breast: the controversy drags on?: a systematic review and meta-analysis. Breast Cancer Res Treat. 2021;185(1):21–37.
doi: 10.1007/s10549-020-05924-8
pubmed: 32935237
Mihai R, Callagy G, Qassid OL, et al. Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. Histopathology. 2021;78(6):871–81.
doi: 10.1111/his.14316
pubmed: 33325544
Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol. 2012;65(1):69–76.
doi: 10.1136/jclinpath-2011-200368
pubmed: 22049216
Borhani-Khomani K, Talman ML, Kroman N, Tvedskov TF. Risk of local recurrence of benign and borderline phyllodes tumors: a Danish population-based retrospective study. Ann Surg Oncol. 2016;23:1543–8. https://doi.org/10.1245/s10434-015-5041-y .
doi: 10.1245/s10434-015-5041-y
pubmed: 26714948
Cowan ML, Argani P, Cimino-Mathews A. Benign and low-grade fibroepithelial neoplasms of the breast have low recurrence rate after positive surgical margins. Mod Pathol. 2016;29(3):259–65.
doi: 10.1038/modpathol.2015.157
pubmed: 26743469
Noordman PCW, Klioueva NM, Weimann MN, Borgstein PJ, Vrouenraets BC. Phyllodes tumors of the breast: a retrospective analysis of 57 cases. Breast Cancer Res Treat. 2020;181(2):361–7.
doi: 10.1007/s10549-020-05620-7
pubmed: 32277376
Teo JY, Cheong CS, Wong CY. Low local recurrence rates in young Asian patients with phyllodes tumours: less is more. ANZ J Surg. 2012;82(5):325–8.
doi: 10.1111/j.1445-2197.2012.06045.x
pubmed: 22507352
Ogunbiyi S, Perry A, Jakate K, Simpson J, George R. Phyllodes tumour of the breast and margins: how much is enough. Can J Surg. 2019;62(1):E19–21.
doi: 10.1503/cjs.005718
pubmed: 30694037
pmcid: 6351251
Salvadori B, Cusumano F, Del Bo R, et al. Surgical treatment of phyllodes tumors of the breast. Cancer. 1989;63:2532–6.
doi: 10.1002/1097-0142(19890615)63:12<2532::AID-CNCR2820631229>3.0.CO;2-Q
pubmed: 2541890
Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68(1):5–21.
doi: 10.1111/his.12876
pubmed: 26768026
pmcid: 5027876
Wen B, Mousadoust D, Warburton R, et al. Phyllodes tumours of the breast: outcomes and recurrence after excision. Am J Surg. 2020;219(5):790–4.
doi: 10.1016/j.amjsurg.2020.02.048
pubmed: 32145921
Sawalhi S, Al-Shatti M. Phyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis. Ann Saudi Med. 2013;33:162–8.
doi: 10.5144/0256-4947.2013.162
pubmed: 23563006
pmcid: 6078618
Sotheran W, Domjan J, Jeffrey M, Wise MH, Perry PM. Phyllodes tumours of the breast—a retrospective study from 1982–2000 of 50 cases in Portsmouth. Ann R Coll Surg Engl. 2005;87:339–44.
doi: 10.1308/003588405X51128
pubmed: 16176692
pmcid: 1963973
Chng TW, Lee JYH, Lee CS, Li H, Tan MH, Tan PH. Validation of the Singapore nomogram for outcome prediction in breast phyllodes tumours: an Australian cohort. J Clin Pathol. 2016;69:1124–6.
doi: 10.1136/jclinpath-2016-203951
pubmed: 27466383
Rayzah M. Phyllodes tumors of the breast: a literature review. Cureus. 2020;12(9):e10288.
pubmed: 32923300
pmcid: 7478785
Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol. 2014;21:1222–30. https://doi.org/10.1245/s10434-013-3395-6 .
doi: 10.1245/s10434-013-3395-6
pubmed: 24306659
Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008;70:492–500.
doi: 10.1016/j.ijrobp.2007.06.059
pubmed: 17931796
Boutrus RR, Khair S, Abdelazim Y, et al. Phyllodes tumors of the breast: adjuvant radiation therapy revisited. Breast. 2021;58:1–5.
doi: 10.1016/j.breast.2021.03.013
pubmed: 33865208
pmcid: 8079270
Barth RJ, Wells WA, Mitchell SE, et al. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16:2288–94. https://doi.org/10.1245/s10434-009-0489-2 .
doi: 10.1245/s10434-009-0489-2
pubmed: 19424757
pmcid: 5053421
Neron M, Sajous C, Thezenas S, et al. Surgical margins and adjuvant therapies in malignant phyllodes tumors of the breast: a multicenter retrospective study. Ann Surg Oncol. 2020;27(6):1818–27. https://doi.org/10.1245/s10434-020-08217-y .
doi: 10.1245/s10434-020-08217-y
pubmed: 31989361